Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Data Accumulate to Suggest HLA-B27 Status May Drive Axial Phenotype in SpA

Lara C. Pullen, PhD  |  May 20, 2022

HLA-B27 may be a phenotypic expression of axial spondyloarthritis (SpA), according to a large international study. The study found patients with axial SpA who were positive for HLA-B27 had more severe radiographic damage than those who were negative for HLA-B27, and three quarters of study patients with ankylosis spondyloarthritis were HLA-B27 positive.

Filed under:Axial SpondyloarthritisConditionsPsoriatic ArthritisResearch Rheum Tagged with:Arthritis Care & ResearchAxial Psoriatic Arthritis (axPsA)axial spondyloarthritis (SpA)HLA-B27phenotypePsoriatic Arthritis

Medication Preferences & Current Practices for PsA

Michele B. Kaufman, PharmD, BCGP  |  May 11, 2022

With many new agents designed to treat PsA, rheumatologists and patients have options. Schwartzman et al. examined the real-world use of different treatments and ranked patient medication preferences.

Filed under:ACR ConvergenceConditionsDrug UpdatesMeeting ReportsPsoriatic Arthritis Tagged with:ACR Convergence 2021PsAPsoriatic Arthritis

Imaging of Axial Psoriatic Arthritis

Walter P. Maksymowych, MB ChB, FACP, FRCP(C)  |  May 9, 2022

The axial phenotype of psoriatic arthritis (axPsA) is an excellent example of a major controversy in rheumatology that has become the focus of attention because of the emergence of new therapies with different mechanisms of action for alleviating joint inflammation. It was first described in 1961 but, until recently, it has largely remained under the…

Filed under:Axial SpondyloarthritisConditionsPsoriatic Arthritis Tagged with:Ankylosing SpondylitisAxial Psoriatic Arthritis (axPsA)axial skeletal inflammationMagnetic resonance imaging (MRI)Psoriatic ArthritisradiographX-ray

Axial Disease in Psoriatic Arthritis

Philip Helliwell, DM, PhD, FRCP  |  May 6, 2022

When Moll and Wright first described the spondyloarthritides in the early 1970s, the archetype of the group was ankylosing spondylitis (AS).1 The shared clinical features of the spondyloarthritides were sacroiliitis; asymmetric large joint peripheral arthritis; psoriasis or psoriaform skin lesions, including keratoderma blennorrhagica; uveitis; and bowel inflammation. Moll and Wright described five clinical subgroups of…

Filed under:Axial SpondyloarthritisConditionsPsoriatic Arthritis Tagged with:Ankylosing SpondylitisAxial Psoriatic Arthritis (axPsA)Psoriatic Arthritis

Risk of Adverse Outcomes Due to COVID-19 May Be Lower with TNF Inhibitor Monotherapy

Katie Robinson  |  May 5, 2022

Findings support the continued use of TNF inhibitor monotherapy in individuals with immune-mediated inflammatory diseases. In the study, these patients had a lower risk of hospitalization or death caused by COVID-19 than patients on other commonly prescribed treatment regimens

Filed under:Conditions Tagged with:COVID-19COVID-19 Global Rheumatology Allianceimmune-mediated inflammatory diseases (IMIDs)monotherapyTNF inhibitors

New Tech Provides Insights Into the Pathogenesis of Psoriatic Arthritis

Maria de la Luz Garcia-Hernandez, PhD, & Christopher Ritchlin, MD, MPH  |  May 5, 2022

The etiology of psoriatic arthritis (PsA) is poorly understood but current evidence supports an interaction between genetic and environmental factors that coalesce to promote local tissue inflammation.1-3 The pivotal cytokines that underlie the local inflammatory response in a wide range of tissues are interleukin (IL) 23, IL-17 and tumor necrosis factor (TNF).4 The central contribution…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

Looking to Psoriatic Arthritis History to Disrupt Current Thinking

Rebecca H. Haberman, MD, & Jose U. Scher, MD  |  May 4, 2022

As the cloud moved away from the tent, Miriam’s skin suddenly became diseased, as white as snow. When Aaron turned toward her, he saw that she was diseased. —Numbers 12:10 For 29 years he [Fray Pedro de Urraca] was afflicted by … pain, suffering it at once in all the joints of his body, with…

Filed under:ConditionsPsoriatic Arthritis Tagged with:Psoriatic Arthritis

FDA Approves Risankizumab-rzaa for PsA

Michele B. Kaufman, PharmD, BCGP  |  April 20, 2022

Two recent trials demonstrated the safety and efficacy of risankizumab-rzaa for the treatment of adults with active psoriatic arthritis.

Filed under:Biologics/DMARDsDrug Updates Tagged with:FDA approvalPsAPsoriatic Arthritisrisankizumab-rzaaU.S. Food and Drug Administration (FDA)

Real-Life Rheumatology: Clinical Pearls for Psoriatic Arthritis

Jason Liebowitz, MD, FACR  |  March 23, 2022

At the 17th Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases meeting, Ana-Maria Orbai, MD, MHS, discussed lessons learned from the cases of several patients with psoriatic arthritis.

Filed under:ConditionsMeeting ReportsPsoriatic Arthritis Tagged with:Advances in the Diagnosis and Treatment of the Rheumatic Diseases meetingClinical RheumatologyPractice PearlsPsoriatic Arthritis

Spring 2022’s Awards, Appointments & Announcements in Rheumatology

Gretchen Henkel  |  March 14, 2022

Martin Kriegel, MD, PhD, Receives 2021 Lupus Insight Award “I have always found the conundrum of autoimmunity interesting. It’s fascinating to find out why the immune system attacks the body, how it can distinguish self from non-self,” says Martin Kriegel, MD, PhD, head of the Department of Translational Rheumatology & Immunology, Institute of Musculoskeletal Medicine,…

Filed under:Awards Tagged with:Dr. Christopher T. RitchlinDr. Mariana J. KaplanDr. Martin Kriegel

  • « Previous Page
  • 1
  • …
  • 13
  • 14
  • 15
  • 16
  • 17
  • …
  • 55
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences